Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China; Beijing Key Laboratory of Nasal Diseases, Beijing Laboratory of Allergic Diseases, Beijing Institute of Otolaryngology, Beijing, China; Key Laboratory of Otolaryngology Head and Neck Surgery (Ministry of Education of China), Beijing Institute of Otolaryngology, Beijing, China; Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.
Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China; Beijing Key Laboratory of Nasal Diseases, Beijing Laboratory of Allergic Diseases, Beijing Institute of Otolaryngology, Beijing, China; Key Laboratory of Otolaryngology Head and Neck Surgery (Ministry of Education of China), Beijing Institute of Otolaryngology, Beijing, China; Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.
J Allergy Clin Immunol. 2023 May;151(5):1191-1203.e3. doi: 10.1016/j.jaci.2023.02.005. Epub 2023 Mar 21.
Cystatin SN, encoded by CST1, belongs to the type 2 (T2) cystatin protein superfamily. In the past decade, several publications have highlighted the association between cystatin SN and inflammatory airway diseases including chronic rhinosinusitis, rhinitis, asthma, chronic obstructive pulmonary disease, and chronic hypersensitivity pneumonitis. It is, therefore, crucial to understand the role of cystatin SN in the wider context of T2 inflammatory diseases. Here, we review the expression of cystatin SN in airway-related diseases with different endotypes. We also emphasize the physiological and pathological roles of cystatin SN. Physiologically, cystatin SN protects host tissues from destructive proteolysis by cysteine proteases present in the external environment or produced via internal dysregulated expression. Pathologically, the secretion of cystatin SN from airway epithelial cells initiates and amplifies T2 immunity and subsequently leads to disease. We further discuss the development of cystatin SN as a T2 immunity marker that can be monitored noninvasively and assist in airway disease management. The discovery, biology, and inhibition capability are also introduced to better understand the role of cystatin SN in airway diseases.
半胱氨酸蛋白酶抑制剂 SN(Cystatin SN)由 CST1 基因编码,属于 2 型(T2)半胱氨酸蛋白酶抑制剂蛋白超家族。在过去的十年中,已有多项研究强调了半胱氨酸蛋白酶抑制剂 SN 与包括慢性鼻-鼻窦炎、鼻炎、哮喘、慢性阻塞性肺疾病和慢性过敏性肺炎在内的炎症性气道疾病之间的关联。因此,了解半胱氨酸蛋白酶抑制剂 SN 在更广泛的 T2 炎症性疾病背景下的作用至关重要。在这里,我们回顾了半胱氨酸蛋白酶抑制剂 SN 在具有不同表型的气道相关疾病中的表达情况。我们还强调了半胱氨酸蛋白酶抑制剂 SN 的生理和病理作用。在生理上,半胱氨酸蛋白酶抑制剂 SN 通过阻止外源性或内源性异常表达的半胱氨酸蛋白酶对宿主组织的破坏性蛋白水解,从而保护宿主组织。在病理条件下,半胱氨酸蛋白酶抑制剂 SN 由气道上皮细胞分泌,引发并放大 T2 免疫反应,进而导致疾病。我们进一步讨论了将半胱氨酸蛋白酶抑制剂 SN 作为 T2 免疫标志物进行监测的潜力,该标志物可以进行非侵入性监测,有助于气道疾病的管理。此外,我们还介绍了对半胱氨酸蛋白酶抑制剂 SN 的发现、生物学特性和抑制能力的研究,以更好地理解其在气道疾病中的作用。